Open access · CC-BY
via OpenAlex
Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
Ouissam Al Jarroudi, Hind Chibani, Sami Aziz Brahmi, Afqir Said
Therapeutic Advances in Medical Oncology · 2024 · ▲ 17 citations
Deregulated nutrient-sensing
Altered intercellular communication
Rapamycin / mTOR inhibition
Human
Review
Abstract
Pancreatic cancer (PC) is an aggressive disease that is challenging to treat and is associated with a high mortality rate. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), and the existing treatment options are insufficient for PDAC patients. Due to the complexity and heterogeneity of PDAC, personalized medicine is necessary for effectively treating this illness. To achieve this, it is essential to understand the mechanism of PDAC carcinogenesis. Targeted therapies are a promising strategy to improve patient outcomes. Aberrant activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (PI3K/AKT/mTOR) signaling pathway plays a crucial role in PC pathogenesis, from initiation to progression. This review provides a comprehensive overview of the current state of knowledge regarding the PI3K pathway in PDAC, summarizes clinical data on PI3K pathway inhibition in PDAC, and explores potential effective combinations that are a promising direction requiring further investigation in PDAC.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1177/17588359241284911
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Jarroudi, O.A., Chibani, H., Brahmi, S.A., & Said, A. (2024). Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. <em>Therapeutic Advances in Medical Oncology</em>. https://doi.org/10.1177/17588359241284911
Vancouver
Jarroudi OA, Chibani H, Brahmi SA, Said A. Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. Therapeutic Advances in Medical Oncology. 2024. doi:10.1177/17588359241284911.
BibTeX
@article{ouissam2024Inhibi,
title = {Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?},
author = {Ouissam Al Jarroudi and Hind Chibani and Sami Aziz Brahmi and Afqir Said},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
doi = {10.1177/17588359241284911},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cells 2023
Open access · CC-BY
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
Frontiers in Neurology 2025
Open access · CC-BY
Receptor-mediated mitophagy: a new target of neurodegenerative diseases
Biomedicine & Pharmacotherapy 2021
Open access · CC-BY
Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential
International Journal of Molecular Sciences 2021
Open access · CC-BY
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Journal of Clinical Medicine 2020
Open access · CC-BY
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Signal Transduction and Targeted Therapy 2021
Open access · CC-BY